Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 60 Recurrence 11 Neoplasms, Plasma Cell 3 Smoldering Multiple Myeloma 2 Hematologic Neoplasms 2 Neoplasms 1 Lymphoma 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 69 fludarabine phosphate 63 Busulfan 45 Peripheral Blood Stem Cell Transplantation 42 Tacrolimus 40 Mycophenolic Acid 37 Filgrastim 35 Antilymphocyte Serum 35 fludarabine 31 Cyclosporine 30 Radiotherapy 29 Melphalan 29 Whole-Body Irradiation 27 Methotrexate 24 Etoposide 20 Cord Blood Stem Cell Transplantation 18 Biopsy 18 Methylprednisolone 16 Specimen Handling 15 Rituximab 14 Magnetic Resonance Spectroscopy 13 Alemtuzumab 12 Stem Cell Transplantation 11 Granulocyte Colony-Stimulating Factor 11 Cytarabine 11 sargramostim 9 Sirolimus 9 Prednisone 9 Dexamethasone 9 plerixafor 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × elotuzumab × Plasma cell × Clear all

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡